Company
Business
Stem Cell Therapy
Organoid
CDMO Business
Anti-Inflammatory Mechanism of Umbilical Cord Blood–Derived Stem Cells
- Anti-inflammatory mechanism of action of umbilical cord blood–derived stem cells in rheumatoid arthritis. In rheumatoid arthritis, pro-inflammatory M1 macrophages play a central role in disease progression by producing inflammatory cytokines such as TNF-α and IL-1β. When exposed to this inflammatory microenvironment, Furestem-RA inj. is activated and secretes immunomodulatory factors, including prostaglandin E2 (PGE-2) and Activin A. These factors suppress M1 macrophage activity and promote polarization toward the anti-inflammatory M2 macrophage phenotype. Activated M2 macrophages subsequently secrete interleukin-10 (IL-10), contributing to the resolution of inflammation and regeneration of damaged tissues.
Establishment of a Cytokine Library Derived from Furestem-RA inj.
- The cytokine secretion profile of umbilical cord blood–derived stem cells, the active ingredient of Furestem-RA injection, was systematically analyzed to establish a comprehensive cytokine library. Using Gene Ontology (GO) analysis, the secreted cytokines were functionally classified according to their roles in inflammatory and immune regulatory processes.
- This integrated analytical approach provides mechanistic insights into the immunomodulatory action of Furestem-RA inj. and serves as a scientific basis for identifying potential therapeutic mechanisms and biomarkers for inflammatory and immune-related diseases.
Mechanism of Action and Therapeutic Efficacy of Furestem-RA inj.
- The therapeutic efficacy of Furestem-RA inj. is primarily mediated through the modulation of macrophage-mediated inflammatory responses. Specifically, Furestem-RA inj. demonstrates potent inhibitory effects on the secretion of the pro-inflammatory cytokine TNF-α from M1 macrophages, which are key drivers of inflammation.
- Furestem-RA inj. promotes the differentiation and activation of anti-inflammatory M2 macrophages, leading to enhanced secretion of the anti-inflammatory cytokine interleukin-10 (IL-10).
- Through this dual immunomodulatory mechanism—suppression of pro-inflammatory signaling and activation of anti-inflammatory pathways—Furestem-RA inj. contributes to inflammation resolution and immune homeostasis.
Preclinical efficacy of Furestem-RA inj
- In a preclinical rheumatoid arthritis animal model, treatment with Furestem-RA inj. significantly improved arthritis scores, demonstrating its therapeutic potential in alleviating inflammatory joint pathology.